Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: A comparison with human regular insulin during a three-meal test period

Diabetes Care

Volumn 20, Issue 8, 1997, Pages 1279-1286

  Jacobs, Maarten A J M ^a   Keulen, Erik T P ^a   Kanc, Karin ^a   Casteleijn, Sandrina ^a   Scheffer, Peter ^a   Devillé, Walter ^a   Heine, Robert J ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; SCHOOL CHILD;

EID: 0030743426     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.8.1279     Document Type: Article

References (37)

1. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
2. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341:1306-1309, 1993
3. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-985, 1993
4. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH, Service FJ: Control of blood sugar in insulin dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional insulin therapy. N Engl J Med 303:1313-1318, 1980
5. Reeves ML, Seigler DE, Ryan EA Skyler JS: Glycaemic control in insulin dependent diabetes mellitus: comparison of outpatient intensified convential therapy with continuous subcutaneous insulin infusion. Am J Med 72:673-680, 1982
6. Houtzagers CMGJ, Berntzen PA, van der Stap H, Van Maarschalkerweerd WWA, Lanting P, Boen-Tan I, Heine RJ: Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long term cross-over comparison. Diabet Med 6:416-421, 1989
7. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes Care 7:188-199, 1984
8. Gardner DF, Arakaki RF, Podet EJ, Nell LJ, Thomas JW, Field JB: The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessments using a glucose clamp technique. J Clin Endocrinol Metab Res 63:689-694, 1986
9. Brange J, Owens DR, Kang S, Vølund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
10. Brems DN, Alter LA, Beckage MJ, Chance RE, DiMarchi R, Green LK, Long HB, Pekar AH, Shields JE, Frank BH: Altering the association properties of insulin by amino acid replacement. Protein Eng 5:527-533, 1992
11. Frank BH, Chance RE, DiMarchi RD, Shields JE: Manipulation of proline in the B-chain produces monomeric insulins (Abstract). Diabetes 40 (Suppl. 1):207A, 1990
12. Shaw W, Su KSE: Biological aspects of a new insulin analog: Lys(28)Pro(B29)-human insulin (Abstract). Diabetes 40 (Suppl. 1):464A, 1991
13. Radziuk J, Candas B, Davies J, Yang M, DiMarchi R, Chance R: The absorption kinetics of subcutaneously injected insulin and two monomeric analogs (Abstract). Diabetes 40 (Suppl. 1):465A, 1991
14. Radziuk J, Davies S, Pye S, DiMarchi R, Shields J, Chance R: Subcutaneous absorption of fast acting insulin analogs: kinetics and bioeffectiveness (Abstract). Diabetologia 35 (Suppl. 1):A3, 1992
15. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: Lys(B28)Pro(B29)-human insulin: a rapidly absorbed analog of human insulin. Diabetes 43:396-402, 1994
16. Kang S, Brange J, Burch A, Volund A, Owens D: Subcutaneous insulin absorption explained by insulin's physicochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:942-948, 1991
17. Brunelle RL, Anderson JH, Vignati L: Decreased rate of hypoglycaemia in association with improved metabolic control with insulin lispro (Abstract). Diabetologia 37(Suppl. 1):A78, 1994
18. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, Chase HP: Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 13:47-52, 1996
19. Jacobs MAJM, Salobir B, Aarsen M, Van Iperen A, Heine RJ: Hypoglycaemic thresholds for the glucose counterregulatory responses to Lys(B28)Pro(B29) human insulin analog (Abstract). Horm Metab Res 26:A34, 1994
20. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28)Pro(29)] in type 1 diabetes mellitus. Diabetologia 37:713-720, 1994
21. Tuominen JA, Karonen SL, Koivisto VA: Hypoglycaemic effect of short acting insulin analogue during exercise in type 1 diabetes. Diabetologia 38:106-115, 1995
22. Fineberg NS, Fineberg SE, Anderson JH., Birkett M, Gibson RG, Hufferd S: Does lyspro (B28,29) human insulin analog altered immunogenecity in patients with type 1 diabetes? (Abstract) Diabetologia 37 (Suppl. 1):A167, 1994
23. Slieker LJ, Sundell K: Modification in the 28-29 position of the insulin B-chain alters binding to the IGF-1 receptor with minimal effect on insulin receptor binding (Abstract). Diabetes 40 (Suppl. 1):168A, 1991
24. Jørgensen LN, Dideriksen LN, Drejer K: Carcinogenic effect of the human insulin analogue B10 Asp in female rats (Abstract). Diabetologia 36 (Suppl. 1):A3, 1993
25. Gabbay KH, Hasty K, Breslow JL, Ellison RC, Brunn HF, Gallow PM: Glycosylated haemoglobins, a long term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab 44:859-864, 1977
26. Koch DD, Feldbruegge DH: Optimized kinetic method for automated determination of β-hydroxybutyrate. Clin Chem 33:1761-1766, 1987
27. Hills M, Armitage P: The two-period cross-over clinical trial. Br J Clin Pharmacol 8:7-20, 1979
28. Heinemann L, Heise T, Wahl LCh, Trautmann ME, Ampudia J, Starke AAR, Berger M: Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28),Pro(B29)] human insulin. Diabet Med 13:625-629
29. Skyler JS, Seigler DE, Reeves ML: A comparison of insulin regimens in insulin dependent diabetes mellitus (Abstract). Diabetes Care 5 (Suppl. 1):11-18, 1982
30. Oswald GA, Yudkin JS: A within patient cross-over trial of 4 insulin regimens in an antibody-negative, C-peptide negative patients. Diabetes Res 4:85-89, 1987
31. Marshall SM, Home PD, Taylor R, Alberti KGGM: Continuous subcutaneous insulin infusion vs. injection therapy: a randomised cross-over trial under usual diabetic clinic conditions. Diabet Med 4:521-525, 1987
32. Houtzagers CMGJ, Velde van der EA: Multiple daily insulin injections: a multicentre study on acceptability and efficacy. Neth J Med 33:16-25, 1988
33. Selam JL, Raccah D, Jeandidier N, Lozano JL, Waxman K, Charles MA: Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps vs. intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 15:53-58, 1992
34. Selam J, Kashyap M, Alberti KGGM, Lozano JL, Hanna M, Turner D, Charles MA: Comparison of intraperitoneal and subcutaneous insulin administration on lipids apolipoproteins, fuel metabolites and hormones in type 1 diabetes mellitus. Metabolism 38:908-912, 1989
35. Ruotolo G, Micossi P, Galimberti G, Librenti MC, Petrella G, Marcovina S, Pozza G, Howard BV: Effects of intraperitoneal vs. subcutaneous insulin administration on lipoprotein metabolism in type 1 diabetes. Metabolism 39:598-604, 1990
36. Georgopoulos A, Saudek C: Normalization of composition of triglyceride-rich lipoprotein subfractions in diabetic subjects during insulin infusion with programmable implantable medication system. Diabetes Care 15:19-26, 1992
37. Bagdade JD, Dunn FL: Effects of insulin treatment on lipoprotein composition and function in patients with IDDM. Diabetes 31 (Suppl. 2):107-110, 1992